Update on New Convertible Facility Agreement
Updated : 07:00
11 October 2021
Kropz Plc
("Kropz" or the "Company")
Update on New Convertible Facility Agreement
Kropz Plc (AIM: KRPZ), an emerging African phosphate explorer and developer, announced on 29 September 2021 that it had entered into a new conditional convertible equity facility of up to ZAR 200 million ("New ZAR Equity Facility"), with ARC Fund ("ARC"), the Company's major shareholder, in order to deliver the Company's Elandsfontein phosphate project to first revenue.
Further to that announcement, the Company is pleased to report that it has now received approval from the South African Reserve Bank ("SARB") for the New ZAR Equity Facility. The New ZAR Equity Facility is also conditional on shareholder approval which, as previously announced, is being sought from the Company's shareholders at a General Meeting to be held in London at 11:30 on 15 October 2021.
For further information visit www.kropz.com or contact:
Kropz Plc | |
Mark Summers (CEO) | +27 (0) 79 744 8708 |
Grant Thornton UK LLP | Nominated Adviser |
Samantha Harrison Harrison Clarke George Grainger | +44 (0) 20 7383 5100 |
Hannam & Partners | Broker |
Andrew Chubb Ernest Bell | +44 (0) 20 7907 8500 |
Tavistock | Financial PR & IR (UK) |
Nick Elwes Jos Simson Oliver Lamb | +44 (0) 207 920 3150 kropz@tavistock.co.uk |
R&A Strategic Communications | PR (South Africa) |
James Duncan | +27 (0) 11 880 3924 james@rasc.co.za |
About Kropz Plc
Kropz is an emerging African explorer and developer of plant nutrient feed minerals with phosphate projects in South Africa and in the Republic of Congo. The vision of the Group is to become a leading independent phosphate rock producer and to develop into an integrated, mine-to-market plant nutrient company focusing on sub-Saharan Africa.
-ENDS-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.